TY - JOUR
T1 - Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes
T2 - Restorative effects of (-)-epicatechinrich cocoa
AU - Taub, Pam R.
AU - Ramirez-Sanchez, Israel
AU - Ciaraldi, Theodore P.
AU - Gonzalez-Basurto, Silvia
AU - Coral-Vazquez, Ramon
AU - Perkins, Guy
AU - Hogan, Michael
AU - Maisel, Alan S.
AU - Henry, Robert R.
AU - Ceballos, Guillermo
AU - Villarreal, Francisco
PY - 2013/10
Y1 - 2013/10
N2 - HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function. We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al. (2012) Clin. Trans. Sci. 5, 43-47]. We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure. In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed. Western blot analysis, immunohistochemistry and electron microscopy were used. We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline. ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration. VO2max increased (~24%) but did not reach statistical significance. These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.
AB - HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function. We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al. (2012) Clin. Trans. Sci. 5, 43-47]. We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure. In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed. Western blot analysis, immunohistochemistry and electron microscopy were used. We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline. ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration. VO2max increased (~24%) but did not reach statistical significance. These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.
KW - Atrophy
KW - Dystrophin
KW - Mitochondrion
KW - Myofibre
KW - Skeletal muscle
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84880175168&partnerID=8YFLogxK
U2 - 10.1042/CS20130023
DO - 10.1042/CS20130023
M3 - Artículo
C2 - 23642227
SN - 0143-5221
VL - 125
SP - 383
EP - 389
JO - Clinical Science
JF - Clinical Science
IS - 8
ER -